Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain

Molecular Pharmaceutics

Volumn 13, Issue 5, 2016, Pages 1501-1507

  Qi, Jinxu ^a   Zhang, Yao ^a   Gou, Yi ^a   Zhang, Zhenlei ^a   Zhou, Zuping ^a   Wu, Xiaoyang ^b   Yang, Feng ^a   Liang, Hong ^a  

^a GUANGXI NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

copper(II) compound; human serum albumin; pro drug; therapeutic effect; tumor targeting

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; CUPRIC ION; FATTY ACID; HISTIDINE; HUMAN SERUM ALBUMIN; HYDROGEN; PRODRUG; ANTINEOPLASTIC AGENT; COPPER; LIGAND; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IC50; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION; APOPTOSIS; BINDING SITE; CHEMICAL PHENOMENA; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; NEOPLASMS; PH; PROCEDURES;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; COPPER; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; NEOPLASMS; PRODRUGS; SERUM ALBUMIN;

EID: 84968724893     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00938     Document Type: Article

References (58)

1. Kelland, L. The resurgence of platinum-based cancer chemotherapy Nat. Rev. Cancer 2007, 7, 573-584 10.1038/nrc2167
2. Sakaeda, T.; Kadoyama, K.; Okuno, Y. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations Int. J. Med. Sci. 2011, 8, 487-491 10.7150/ijms.8.487
3. Gasser, G.; Ott, I.; Metzler-Nolte, N. Organometallic anti-cancer compounds J. Med. Chem. 2011, 54, 3-25 10.1021/jm100020w
4. Medici, S.; Peana, M.; Nurchi, V. M.; Lachowicz, J. I.; Crisponi, G.; Zoroddu, M. A. Noble metals in medicine: Latest advances Coord. Chem. Rev. 2015, 284, 329-350 10.1016/j.ccr.2014.08.002
5. Timerbaev, A. R.; Hartinger, C. G.; Aleksenko, S. S.; Keppler, B. K. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology Chem. Rev. 2006, 106, 2224-2248 10.1021/cr040704h
6. Barry, N. P.; Sadler, P. J. Exploration of the medical periodic table: towards new targets Chem. Commun. 2013, 49, 5106-5131 10.1039/c3cc41143e
7. Lorden, E. R.; Levinson, H. M.; Leong, K. W. Integration of drug, protein, and gene delivery systems with regenerative medicine Drug Delivery Transl. Res. 2015, 5, 168-186 10.1007/s13346-013-0165-8
8. Lainé, A. L.; Passirani, C. Novel metal-based anticancer drugs: a new challenge in drug delivery Curr. Opin. Pharmacol. 2012, 12, 420-426 10.1016/j.coph.2012.04.006
9. Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 2008, 132, 171-183 10.1016/j.jconrel.2008.05.010
10. Garmann, D.; Warnecke, A.; Kalayda, G. V.; Kratz, F.; Jaehde, U. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells J. Controlled Release 2008, 131, 100-106 10.1016/j.jconrel.2008.07.017
11. Yewale, C.; Baradia, D.; Vhora, I.; Misra, A. Proteins: emerging carrier for delivery of cancer therapeutics Expert Opin. Drug Delivery 2013, 10, 1429-1448 10.1517/17425247.2013.805200
12. Elzoghby, A. O.; Samy, W. M.; Elgindy, N. A. Albumin-based nanoparticles as potential controlled release drug delivery systems J. Controlled Release 2012, 157, 168-182 10.1016/j.jconrel.2011.07.031
13. Peters, T. All about Albumin: Biochemistry, Genetics, and Medical Applications; Academic Press: San Diego, CA, 1996.
14. Ghuman, J.; Zunszain, P. A.; Petitpas, I.; Bhattacharya, A. A.; Otagiri, M.; Curry, S. Structural basis of the drug-binding specificity of human serum albumin J. Mol. Biol. 2005, 353, 38-52 10.1016/j.jmb.2005.07.075
15. Zsila, F. Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model Mol. Pharmaceutics 2013, 10, 1668-1682 10.1021/mp400027q
16. Rehman, M. T.; Shamsi, H.; Khan, A. U. Insight into the binding mechanism of imipenem to human serum albumin by spectroscopic and computational approaches Mol. Pharmaceutics 2014, 11, 1785-97 10.1021/mp500116c
17. Yang, F.; Yue, J.; Ma, L.; Ma, Z.; Li, M.; Wu, X.; Liang, H. Interactive associations of drug-drug and drug-drug-drug with IIA subdomain of human serum albumin Mol. Pharmaceutics 2012, 9, 3259-3265 10.1021/mp300322y
18. He, X. M.; Carter, D. C. Atomic structure and chemistry of human serum albumin Nature 1992, 358, 209-215 10.1038/358209a0
19. Elsadek, B.; Kratz, F. Impact of albumin on drug delivery - New applications on the horizon J. Controlled Release 2012, 157, 4-28 10.1016/j.jconrel.2011.09.069
20. Allen, T. M.; Cullis, P. R. Drug delivery systems: entering the mainstream Science 2004, 303, 1818-1822 10.1126/science.1095833
21. Liu, F.; Mu, J.; Xing, B. Recent advances on the development of pharmacotherapeutic agents on the basis of human serum albumin Curr. Pharm. Des. 2015, 21, 1866-1888 10.2174/1381612821666150302115411
22. Fanali, G.; di Masi, A.; Trezza, V.; Marino, M.; Fasano, M.; Ascenzi, P. Human serum albumin: from bench to bedside Mol. Aspects Med. 2012, 33, 209-90 10.1016/j.mam.2011.12.002
23. Gou, Y.; Yang, F.; Liang, H. Designing Prodrugs Based on Special Residues of Human Serum Albumin Curr. Top. Med. Chem. 2015, 16, 996-1008 10.2174/1568026615666150825142908
24. Li, X.; Mu, J.; Liu, F.; Tan, E. W.; Khezri, B.; Webster, R. D.; Yeow, E. K.; Xing, B. Human transport protein carrier for controlled photoactivation of antitumor prodrug and real-time intracellular tumor imaging Bioconjugate Chem. 2015, 26, 955 10.1021/acs.bioconjchem.5b00170
25. Bolling, C.; Graefe, T.; Lübbing, C.; Jankevicius, F.; Uktveris, S.; Cesas, A.; Meyer-Moldenhauer, W. H.; Starkmann, H.; Weigel, M.; Burk, K.; Hanauske, A. R. Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma Invest. New Drugs 2006, 24, 521-527 10.1007/s10637-006-8221-6
26. Yeh, T. K.; Lu, Z.; Wientjes, M. G.; Au, J. L. Formulating paclitaxel in nanoparticles alters its disposition Pharm. Res. 2005, 22, 867-874 10.1007/s11095-005-4581-4
27. Yuan, A.; Wu, J.; Song, C.; Tang, X.; Qiao, Q.; Zhao, L.; Gong, G.; Hu, Y. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity J. Pharm. Sci. 2013, 102, 1626-1635 10.1002/jps.23455
28. Durante, S.; Orienti, I.; Teti, G.; Salvatore, V.; Focaroli, S.; Tesei, A.; Pignatta, S.; Falconi, M. Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model Oncotarget. 2014, 5, 4811-4820 10.18632/oncotarget.2038
29. Isaacs, J. T.; Dalrymple, S. L.; Rosen, D. M.; Hammers, H.; Olsson, A.; Leanderson, T. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment Oncotarget. 2014, 5, 8093-8106 10.18632/oncotarget.2378
30. Merlot, A. M.; Sahni, S.; Lane, D. J.; Fordham, A. M.; Pantarat, N.; Hibbs, D. E.; Richardson, V.; Doddareddy, M. R.; Ong, J. A.; Huang, M. L.; Richardson, D. R.; Kalinowski, D. S. Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells Oncotarget. 2015, 6, 10374-10398 10.18632/oncotarget.3606
31. Gou, Y.; Zhang, Y.; Qi, J.; Kong, L.; Zhou, Z.; Liang, S.; Yang, F.; Liang, H. Binding and Anticancer Properties of Plumbagin with Human Serum Albumin Chem. Biol. Drug Des. 2015, 86, 362-369 10.1111/cbdd.12501
32. Liu, M.; Lim, Z. J.; Gwee, Y. Y.; Levina, A.; Lay, P. A. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity Angew. Chem., Int. Ed. 2010, 49, 1661-1664 10.1002/anie.200906079
33. Zhang, Y.; Ho, A.; Yue, J.; Kong, L.; Zhou, Z.; Wu, X.; Yang, F.; Liang, H. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin Eur. J. Med. Chem. 2014, 86, 449-455 10.1016/j.ejmech.2014.08.071
34. Gou, Y.; Qi, J.; Ajayi, J. P.; Zhang, Y.; Zhou, Z.; Yang, F.; Liang, H. Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain Mol. Pharmaceutics 2015, 12, 3597-3609 10.1021/acs.molpharmaceut.5b00314
35. Gou, Y.; Zhang, Y.; Qi, J.; Zhou, Z.; Yang, F.; Liang, H. Enhancing the copper(II) complexes cytotoxicity to cancer cells through bound to human serum albumin J. Inorg. Biochem. 2015, 144, 47-55 10.1016/j.jinorgbio.2014.12.012
36. Gou, Y.; Zhang, Z.; Qi, J.; Liang, S.; Zhou, Z.; Yang, F.; Liang, H. Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin J. Inorg. Biochem. 2015, 153, 13-22 10.1016/j.jinorgbio.2015.09.004
37. van Rijt, S. H.; Sadler, P. J. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs Drug Discovery Today 2009, 14, 1089-1097 10.1016/j.drudis.2009.09.003
38. Yang, F.; Liang, H. HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach Future Med. Chem. 2016, 8, 89-91 10.4155/fmc.15.179
39. Webb, M. I.; Wu, B.; Jang, T.; Chard, R. A.; Wong, E. W.; Wong, M. Q.; Yapp, D. T.; Walsby, C. J. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions Chem.-Eur. J. 2013, 19, 17031-17042 10.1002/chem.201302671
40. Yang, F.; Ma, Z. Y.; Zhang, Y.; Li, G. Q.; Li, M.; Qin, J. K.; Lockridge, O.; Liang, H. Human serum albumin-based design of a diflunisal prodrug Eur. J. Pharm. Biopharm. 2013, 84, 549-554 10.1016/j.ejpb.2013.01.013
41. Curry, S. Lessons from the crystallographic analysis of small molecule binding to human serum albumin Drug Metab. Pharmacokinet. 2009, 24, 342-357 10.2133/dmpk.24.342
42. Yang, F.; Lee, P.; Ma, Z.; Ma, L.; Yang, G.; Wu, X.; Liang, H. Regulation of amantadine hydrochloride binding with IIA subdomain of human serum albumin by fatty acid chains J. Pharm. Sci. 2013, 102, 84-92 10.1002/jps.23336
43. Ferraro, G.; Massai, L.; Messori, L.; Merlino, A. Cisplatin binding to human serum albumin: a structural study Chem. Commun. 2015, 51, 9436-9439 10.1039/C5CC01751C
44. Yang, F.; Bian, C.; Zhu, L.; Zhao, G.; Huang, Z.; Huang, M. Effect of human serum albumin on drug metabolism: structural evidence of esterase activity ofhuman serum albumin J. Struct. Biol. 2007, 157, 348-55 10.1016/j.jsb.2006.08.015
45. Khan, M. M.; Muzammil, S.; Tayyab, S. Role of salt bridge(s) in the binding and photoconversion of bilirubin bound to high affinity site on human serum albumin Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 2000, 1479, 103-13 10.1016/S0167-4838(00)00050-9
46. Torre, L. A.; Bray, F.; Siegel, R. L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012 Ca-Cancer J. Clin. 2015, 65, 87-108 10.3322/caac.21262
47. Santini, C.; Pellei, M.; Gandin, V.; Porchia, M.; Tisato, F.; Marzano, C. Advances in copper complexes as anticancer agents Chem. Rev. 2014, 114, 815-862 10.1021/cr400135x
48. Tisato, F.; Marzano, C.; Porchia, M.; Pellei, M.; Santini, C. Copper in diseases and treatments, and copper-based anticancer strategies Med. Res. Rev. 2010, 30, 708-749 10.1002/med.20174
49. Sheldrick, G. M. SHELXTL V5.1: Software Reference Manual; Bruker AXS, Inc.: Madison, WI, 1997.
50. Curry, S.; Mandelkow, H.; Brick, P.; Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites Nat. Struct. Biol. 1998, 5, 827-835 10.1038/1869
51. DeLano, W. L. The PyMol. Molecular Graphics System; DeLano ScientiWc: San Carlos, CA, 2004.
52. Yuan, J.; Lovejoy, D. B.; Richardson, D. R. Novel di-2-pyridylderived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment Blood 2004, 104, 1450-1458 10.1182/blood-2004-03-0868
53. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D. R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 14901-14906 10.1073/pnas.0604979103
54. Lovejoy, D. B.; Jansson, P. J.; Brunk, U. T.; Wong, J.; Ponka, P.; Richardson, D. R. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes Cancer Res. 2011, 71, 5871-5880 10.1158/0008-5472.CAN-11-1218
55. Yu, Y.; Suryo Rahmanto, Y.; Richardson, D. R. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy Br. J. Pharmacol. 2012, 165, 148-166 10.1111/j.1476-5381.2011.01526.x
56. Palanimuthu, D.; Shinde, S. V.; Somasundaram, K.; Samuelson, A. G. In vitro and in vivo anticancer activity of copper bis(thiosemicarbazone) complexes J. Med. Chem. 2013, 56, 722-34 10.1021/jm300938r
57. Abou-Zied, O. K.; Al-Shihi, O. I. Characterization of subdomain IIA binding site of human serum albumin in its native, unfolded, and refolded states using small molecular probes J. Am. Chem. Soc. 2008, 130, 10793-10801 10.1021/ja8031289
58. Patra, D.; Barakat, C.; Tafech, R. M. Study on effect of lipophilic curcumin on sub-domain IIA site of human serum albumin during unfolded and refolded states: a synchronous fluorescence spectroscopic study Colloids Surf., B 2012, 94, 354-61 10.1016/j.colsurfb.2012.02.017